Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.6%

6 terminated/withdrawn out of 41 trials

Success Rate

80.0%

-6.6% vs industry average

Late-Stage Pipeline

7%

3 trials in Phase 3/4

Results Transparency

4%

1 of 24 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment reporting

Analytics

N/A
13(43.3%)
Phase 2
6(20.0%)
Phase 1
4(13.3%)
Phase 2/3
3(10.0%)
Phase 4
2(6.7%)
Phase 1/2
1(3.3%)
Phase 3
1(3.3%)
30Total
N/A(13)
Phase 2(6)
Phase 1(4)
Phase 2/3(3)
+3 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (41)

Showing 20 of 41 trials
NCT07741747Not ApplicableNot Yet Recruiting

Impact of Ultra-fast Genetic Diagnosis of Familial Lymphohistiocytosis on the Time to Bone Marrow Transplantation and Overall Survival

Role: collaborator

NCT05789355Not ApplicableCompleted

Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)

Role: collaborator

NCT05053932Completed

Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia

Role: collaborator

NCT02838069Phase 2Completed

A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis

Role: collaborator

NCT03381950Completed

Chronic Kidney Disease - Renal Epidemiology and Information Network

Role: collaborator

NCT03889834Not ApplicableCompleted

Biological Parameters Changes After Autologous Blood Transfusion of Red Blood Cells (200 ml) in Healthy Volunteers.

Role: collaborator

NCT06592703Phase 1Recruiting

Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis

Role: collaborator

NCT07078435Not ApplicableNot Yet Recruiting

Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis

Role: collaborator

NCT01863108Phase 1Completed

Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma

Role: collaborator

NCT06809010Not ApplicableRecruiting

grouP O wholE blooD : storagE leSion impacT And infLammation

Role: lead

NCT07067099Phase 1Not Yet Recruiting

Neutralizing Interferon Type 1 in Hidradenitis Suppurativa

Role: collaborator

NCT02849886Phase 1/2Terminated

T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.

Role: collaborator

NCT06769139Not Yet Recruiting

Evaluation of the Impact of Red Blood Cell Exchange on Thrombo-inflammation in Sickle Cell Disease

Role: collaborator

NCT04345991Phase 2Completed

Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort

Role: collaborator

NCT02763410Completed

Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation

Role: collaborator

NCT06154668Recruiting

Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

Role: collaborator

NCT04169022Not ApplicableCompleted

AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells

Role: collaborator

NCT03599219Not ApplicableCompleted

Platelet Dysfunction in Blood Donors

Role: lead

NCT04076683Not ApplicableCompleted

Algorithm for Apherisis Monitoring and Prescription Assistance in Sickle Cell Patients (ALGODREP)

Role: lead

NCT03570450Phase 1Recruiting

Regenerative Stem Cell Therapy for Stroke in Europe 1-RESSTORE1

Role: collaborator